Joben Bio-Medical Co Ltd is a Taiwan-based company mainly engaged in the development and sale of new plant medicines, local Chinese herbal medicines, health foods and medical beauty products. The Company develops JBM-TC4 plant new drug, which has been patented, used to provide raw materials for cancer treatment drugs.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Taipei Exchange Other stock markets 18/10/2019			5-day change	1st Jan Change
10.50 ^TWD	+0.96%		+8.81%	-

14/08/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	CI
16/04/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	CI

Market Cap	641M 20.42B 562M 518M 485M 909M 60.44B 928M 6.22B 2.41B 29.87B 2.41B 2.35B 104B	P/E 2017	53.5x	P/E 2018	-22.8x
Enterprise Value	867M 27.65B 761M 701M 656M 1.23B 81.83B 1.26B 8.43B 3.26B 40.44B 3.26B 3.19B 140B	EV / Sales 2017	5.87x	EV / Sales 2018	15.8x
Free-Float	82.63%	Yield 2017	0.07%	Yield 2018	-

14/08/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	CI
16/04/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	CI

Director	Title	Age	Since
Wen Tien Huang CHM	Chairman	-	20/05/2010
Man Hsia Chia BRD	Director/Board Member	-	20/05/2010
Chao Yuan Kuo BRD	Director/Board Member	-	24/06/2011

JBM Stock

Stocks

4193

TW0004193008

Biotechnology & Medical Research

Valuation: JBM

Latest news : JBM

Quotes and Performance

Managers and Directors: JBM

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JBM	+0.96%	+8.81%	-	-	21.03M
LONZA GROUP AG	+0.51%	+7.63%	-4.67%	+2.98%	46.2B
REVOLUTION MEDICINES, INC.	+2.19%	+11.71%	+393.31%	+580.42%	38.71B
IQVIA HOLDINGS INC.	+2.53%	+13.93%	+21.38%	-12.81%	31.9B
BEONE MEDICINES AG	+1.65%	+3.61%	+16.04%	+55.62%	31.12B
CELLTRION, INC.	-4.16%	-2.58%	+8.94%	+25.31%	23.77B
ASCENDIS PHARMA A/S	-0.32%	+12.96%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+1.37%	+14.53%	+69.64%	+130.07%	15.05B
EUROFINS SCIENTIFIC SE	-0.58%	+8.00%	+13.43%	+21.35%	13.74B
IONIS PHARMACEUTICALS, INC.	+3.63%	+9.53%	+103.97%	+98.73%	13.42B
Average	+0.78%	+9.10%	+77.76%	+112.71%	23.01B
Weighted average by Cap.	+0.86%	+8.71%	+88.96%	+131.39%

	2017	2018
Net sales	554M 17.66B 486M 448M 419M 786M 52.26B 802M 5.38B 2.08B 25.83B 2.08B 2.03B 89.56B	192M 6.13B 169M 156M 146M 273M 18.15B 279M 1.87B 723M 8.97B 722M 707M 31.11B
Net income	60.66M 1.93B 53.18M 49.02M 45.9M 86.06M 5.72B 87.85M 589M 228M 2.83B 228M 223M 9.81B	-123M -3.93B -108M -99.67M -93.32M -175M -11.63B -179M -1.2B -464M -5.75B -463M -453M -19.94B
Net Debt	2.35M 74.87M 2.06M 1.9M 1.78M 3.33M 222M 3.4M 22.82M 8.83M 110M 8.82M 8.63M 380M	227M 7.23B 199M 183M 172M 322M 21.39B 328M 2.2B 852M 10.57B 851M 833M 36.65B